STOCK TITAN

Butterfly Network to Participate at the TD Cowen 44th Annual Health Care Conference on March 5, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Butterfly Network, Inc. (NYSE: BFLY) will participate in the TD Cowen 44th Annual Health Care Conference in Boston on March 5, 2024. Joseph DeVivo and Heather Getz will present the company's handheld ultrasound technology and software. Investors can schedule one-on-one meetings with the executives.
Positive
  • None.
Negative
  • None.

NEW YORK & BURLINGTON, Mass.--(BUSINESS WIRE)-- Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”) a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced that it will present and host one-on-one investor meetings at the TD Cowen 44th Annual Health Care Conference in Boston on March 5, 2024. Joseph DeVivo, President, Chief Executive Officer & Chairman, and Heather Getz, Executive Vice President & Chief Financial and Operations Officer will present at 9:10am ET.

A webcast of the presentation will be available in the Events & Presentations section of the Butterfly investor website.

To schedule a one-on-one meeting with Mr. DeVivo and Ms. Getz, please reach out to your TD Cowen representative.

About Butterfly Network

Founded by Dr. Jonathan Rothberg in 2011, Butterfly Network is a digital health company with a mission is to democratize medical imaging by making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Butterfly created the world's first handheld single-probe, whole-body ultrasound system using semiconductor technology, Butterfly iQ. The company has continued to innovate, leveraging the benefits of Moore’s Law, to launch its second generation Butterfly iQ+ in 2020, and third generation iQ3 in 2024 – each with increased processing power and performance enhancements. The disruptive technology has been recognized by TIME’s Best Inventions, Fast Company’s World Changing Ideas, CNBC Disruptor 50, and MedTech Breakthrough Awards, among other accolades. With its proprietary Ultrasound-on-Chip™ technology, intelligent software, and educational offerings, Butterfly is paving the way to mass adoption of ultrasound for earlier detection and remote management of health conditions around the world. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about available countries, visit: butterflynetwork.com/choose-your-country.

Butterfly Media:

Liz Learned

Head of Corporate Communications, Butterfly

media@butterflynetwork.com



Butterfly Investors:

Heather Getz

Chief Financial and Operations Officers, Butterfly

investors@butterflynetwork.com



or



Neal Nagarajan

IR Agency Representative, Sloane & Company

(301) 273-5662

nnagaragan@sloanepr.com

Source: Butterfly Network, Inc.

Butterfly Network, Inc. (BFLY) will participate in the TD Cowen 44th Annual Health Care Conference in Boston on March 5, 2024.

Joseph DeVivo, President, Chief Executive Officer & Chairman, and Heather Getz, Executive Vice President & Chief Financial and Operations Officer will present at the conference.

Butterfly Network, Inc. (BFLY) specializes in handheld, whole-body ultrasound technology and intuitive software.

Investors can schedule one-on-one meetings with Mr. DeVivo and Ms. Getz by reaching out to their TD Cowen representative.
Butterfly Network Inc

NYSE:BFLY

BFLY Rankings

BFLY Latest News

BFLY Stock Data

Irradiation Apparatus Manufacturing
Manufacturing
Link

About BFLY

butterfly network operates at the cutting edge of multiple engineering and scientific disciplines and strives to bring together world-class talent in computer science, physics, and electrical engineering. the company is privately held and well funded by a small group of extraordinarily successful serial entrepreneurs. the company is in the rare position of being able to focus 100% of its efforts on product and intellectual property development rather than fundraising.